original ) (raw )QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK)
Julitha Rembet
Proceedings of the 3rd International Conference on Computation for Science and Technology, 2015
View PDFchevron_right
QSAR and Molecular Docking Studies on a Series of Cinnamic Acid Analogues as Epidermal Growth Factor Receptor (EGFR) Inhibitors
Satyaprakash Gupta
Letters in Drug Design & Discovery, 2016
View PDFchevron_right
Targeting EGFR Tyrosine Kinase: Design, Synthesis and Biological Evaluation of Novel Quinazolinone Derivatives
omid hosseini
Iranian Journal of Pharmaceutical Research
View PDFchevron_right
Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors
Yehia Mohamed
European journal of medicinal chemistry, 2018
View PDFchevron_right
Synthesis, Antitumor Activities and Molecular Modelling of 4-Anilinoquinazoline Derivatives as EGFR-TK Inhibitors
Rania Gomaa
View PDFchevron_right
Virtual Screening and Molecular Docking of 4,6,7-Tri Substituted Quinazoline Derivatives as Potential EGFR Inhibitors
Ahmad F Eweas
View PDFchevron_right
Molecular Docking Analysis on Epidermal Growth Factor Receptor Wild Type (EGFRwt) with Quinazoline Derivative Compounds as Tyrosine Kinase Inhibitors
herlina rasyid
2017
View PDFchevron_right
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile Inhibitors of Epidermal Growth Factor Receptor Kinase and Their Bioisosteric Relationship to the 4-Anilino-6,7-dialkoxyquinazoline Inhibitors
Ramaswamy Nilakantan
Journal of Medicinal Chemistry, 2000
View PDFchevron_right
Structure based design and anti-breast cancer evaluation of some novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor inhibitors
Zahra Rezaei
Research in Pharmaceutical Sciences, 2018
View PDFchevron_right
Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor
Mohamed Elsawy
European Journal of Medicinal Chemistry, 2016
View PDFchevron_right
6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity
Ramaswamy Nilakantan
Journal of Medicinal Chemistry, 2001
View PDFchevron_right
Design of New Quinazoline Derivative as EGFR (Epidermal Growth Factor Receptor) Inhibitor through Molecular Docking and Dynamics Simulation
herlina rasyid
Indonesian Journal of Chemistry, 2020
View PDFchevron_right
Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
Manal Alossaimi
Molecules, 2021
View PDFchevron_right
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle
azim ansari
Bioorganic & Medicinal Chemistry, 2017
View PDFchevron_right
Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: Identification of new scaffolds for potent EGFR tyrosine kinase inhibitors
Takahisa Yamazaki
Bioorganic & Medicinal Chemistry Letters, 2007
View PDFchevron_right
Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach
Malleshappa Noolvi
Arabian Journal of Chemistry, 2013
View PDFchevron_right
Design and synthesis of 4-substituted quinazolines as potent EGFR inhibitors with anti-breast cancer activity
Naja Magdy
Anti-cancer agents in medicinal chemistry, 2016
View PDFchevron_right
Benzofuran–appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies
Marole Maluleka
Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
View PDFchevron_right
Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor
Gordon Rewcastle
Journal of Medicinal Chemistry, 1996
View PDFchevron_right
Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study
naglaa abdel-aziz
European Journal of Medicinal Chemistry, 2010
View PDFchevron_right
Quinazoline Derivatives as Anticancer Agents: QSAR, Molecular Docking and in silico Pharmacokinetic Prediction
SIddharth Modi
Indian Journal of Pharmaceutical Education and Research, 2018
View PDFchevron_right
A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design
Malleshappa Noolvi
Journal of Saudi Chemical Society, 2013
View PDFchevron_right
Molecular Modelling and Synthesis of Quinazoline-Based Compounds as Potential Antiproliferative Agents
mohamed Amin said
Chemical and Pharmaceutical Bulletin, 2014
View PDFchevron_right
Synthesis, molecular modeling and anti-cancer evaluation of a series of quinazoline derivatives
Ahmed Khodair
Carbohydrate Research, 2019
View PDFchevron_right
Identification of oxazolo[4,5-g]quinazolin-2(1H)-one Derivatives as EGFR Inhibitors for Cancer Prevention
Konda Mani Saravanan
Asian Pacific Journal of Cancer Prevention, 2022
View PDFchevron_right
Design, synthesis, docking, ADMET and anticancer evaluations of N -alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors
Marwa Alsulaimany
RSC Advances, 2022
View PDFchevron_right
Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells
Nasser Ismail
European journal of medicinal chemistry, 2018
View PDFchevron_right
Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking
Ahmed Elkamhawy
View PDFchevron_right
In-Silico ADMET Prediction, Structure-Based Drug Design and Molecular Docking Studies of Quinazoline Derivatives as Novel EGFR Inhibitors
IJPSM Journal
International Journal of Pharmaceutical Sciences and Medicine (IJPSM), 2024
View PDFchevron_right
Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFRWT and EGFRT790M : design, synthesis, ADMET and molecular docking
Marwa Alsulaimany
RSC advances, 2024
View PDFchevron_right
Synthesis and Antiproliferative Activity of 2-amino-4-Anilinoquinazoline
Laurence Goossens
2015
View PDFchevron_right
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors
Soyeon Jang
Bioorganic & Medicinal Chemistry Letters, 2018
View PDFchevron_right
Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents
Marawan Ahmed
Journal of Enzyme Inhibition and Medicinal Chemistry, 2014
View PDFchevron_right
Molecular Modeling of Novel Fluorophoric Thiazolo- [2, 3-B] Quinazolinones to Study Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Potency
DR ISWAR BAITHARU
View PDFchevron_right